Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis

ISSN： 1460-2156

Source： Brain, Vol.136, Iss.4, 2013-04, pp. : 1048-1066

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Development of laquinimod for relapsing––remitting multiple sclerosis

By Jeffery Douglas R

Future Neurology, Vol. 3, Iss. 6, 2008-11 ,pp. : 641-648

Future Medicine

Access to resources Recommend Favorite

A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis

By Vollmer T. Sorensen P. Selmaj K. Zipp F. Havrdova E. Cohen J. Sasson N. Gilgun-Sherki Y. Arnold D.

Journal of Neurology, Vol. 261, Iss. 4, 2014-04 ,pp. : 773-783

Springer Publishing Company

Access to resources Recommend Favorite

The B cell response in multiple sclerosis

By Owens Gregory P. Bennett Jeffrey L. Gilden Donald H. Burgoon Mark P.

Neurological Research, Vol. 28, Iss. 3, 2006-04 ,pp. : 236-244

Maney Publishing

Access to resources Recommend Favorite

Disconnection as a mechanism for cognitive dysfunction in multiple sclerosis

By Dineen R. A.

Brain, Vol. 132, Iss. 1, 2009-01 ,pp. : 239-249

Oxford University Press

Access to resources Recommend Favorite

Dendritic cells in the CNS: immune regulators and therapeutic targets for multiple sclerosis treatment

By Zozulya Alla L Reinke Emily K Ling Changying Sandor Matyas Fabry Zsuzsanna

Future Neurology, Vol. 2, Iss. 1, 2007-01 ,pp. : 97-106

Future Medicine

Access to resources Recommend Favorite